辉瑞连续七个交易日亏损

Pfizer (NYSE:PFE) continued losses for seven consecutive sessions, as the stock closed 0.79% lower at $24.54 on Tuesday.

In the preceding six sessions, the company lost over 6.4%. Shares of the company have gone down by over 7% compared to a gain of 13.14% in the broader S&P 500 Index in 2025.

Looking at Seeking Alpha’s Quant rating, PFE has a HOLD rating with a score of 3.45 out of 5. The company was rated A+ for profitability, while it got a D- for growth and a C- for momentum.

According to Wall Street analysts, eight rated the stock a Buy or above, while 15 rated it a Hold, while one considered it a Sell and lower.

However, Oakoff Investments, a quantitative research analyst, rated PFE a Buy, by reporting that Pfizer's stock is poised for recovery, driven by recent corporate news and a three-year reprieve on drug-import tariffs from the Trump administration, strengthening the bullish case despite prior market reactions.

Another analyst, Walter Zelezniak Jr rated a Buy, reporting that technical analysis shows PFE above its 30-week EMA, with bullish short- and long-term momentum and strong buying volume from institutional investors.